Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMABGlobeNewsWire • Monday
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerGlobeNewsWire • 07/01/24
Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the FirmAccesswire • 06/14/24
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingGlobeNewsWire • 06/07/24
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerGlobeNewsWire • 06/05/24
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingGlobeNewsWire • 06/01/24
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingGlobeNewsWire • 06/01/24
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/24
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024GlobeNewsWire • 04/26/24
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a BetZacks Investment Research • 03/28/24
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?Zacks Investment Research • 03/20/24
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?Zacks Investment Research • 03/12/24
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great ChoiceZacks Investment Research • 03/05/24
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsGlobeNewsWire • 03/04/24
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/29/24
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 02/29/24
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to DeclineZacks Investment Research • 02/22/24
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024GlobeNewsWire • 02/16/24
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?Zacks Investment Research • 02/13/24